Hedi Hunt's research while affiliated with University of Tartu and other places

Publications (17)

Article
Full-text available
Oncofetal fibronectin (FN-EDB) and tenascin-C C domain (TNC-C), are nearly absent in 2 extracellular matrix of normal adult tissues but upregulated in malignant tissues. Both FN-EDB 3 and TNC-C are developed as targets of antibody-based therapies. Here we used peptide phage 4 biopanning to identify a novel targeting peptide (PL1, sequence: PPRRGLIK...
Article
Tumor-selective drug conjugates can potentially improve the prognosis for patients affected by glioblastoma (GBM) - the most common and malignant type of brain cancer with no effective cure. Here we evaluated a novel tumor penetrating peptide that targets cell surface p32, LinTT1 (AKRGARSTA), as a GBM targeting ligand for systemically-administered...
Article
Full-text available
Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to imp...
Preprint
During last decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies – a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improv...
Article
Gastrointestinal and gynecological malignancies disseminate in the peritoneal cavity - a condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to improve therapeutic index of anticancer drugs used for PC treatment. Activity of IP anticancer drugs can be further potentiated by encapsulation in nanocarrier...
Article
Full-text available
Peritoneal carcinomatosis results from dissemination of solid tumors in the peritoneal cavity, and is a common site of metastasis in patients with carcinomas of gastrointestinal or gynecological origin. Peritoneal carcinomatosis treatment is challenging as poorly vascularized, disseminated peritoneal micro-tumors are shielded from systemic anticanc...
Article
Targeted delivery of cancer therapeutics using affinity ligands can dramatically improve antitumor efficacy. Over the years a number of homing peptides that upon systemic injection accumulate in solid tumors have been identified by in vivo peptide phage display. In a quest to find homing peptides optimally suited for drug delivery to high-grade gli...
Article
Extracellular matrix protein tenascin C (TNC) is strongly overexpressed in the stroma of many solid tumors. TNC expression is upregulated at the invasive front of tumors while being nearly undetectable in normal adult tissues. TNC-targeted humanized antibodies are undergoing clinical development for targeting compounds to solid tumors. Compared to...
Article
Polymersomes are versatile nanoscale vesicles that can be used for cytoplasmic delivery of payloads. Recently, we demonstrated that pH-sensitive polymersomes exhibit an intrinsic selectivity towards intraperitoneal tumor lesions. A tumor homing peptide, iRGD, harbors a cryptic C-end Rule (CendR) motif that is responsible for neuropilin-1 (NRP-1) bi...
Article
Full-text available
Peritoneal carcinomatosis is present in more than 60% of gastric cancer, 40% of ovarian cancer, and 35% of colon cancer patients. It is the second most common cause of cancer mortality, with a median survival of 1-3 months. Cytoreductive surgery combined with intraperitoneal chemotherapy is the current clinical treatment, but achieving curative dru...
Article
Vähiuuringute üheks keskseks eesmärgiks on vähirakke normaalsetest rakkudest eristavate ravimite väljatöötamine. Kliinilises kasutuses olevate vähiravimite puuduseks on nende vähene selektiivsus ja sellest tingitud kõrvalmõjud normaalsetes kudedes. Artiklis on antud ülevaade suunatud vähiravimite valjatöötamisest ja suundumustest. Suunatud vähiravi...

Citations

... The use of tumor-specific peptides (TSPs) is an important strategy for realizing active tumor targeting. [9,10] Decorating drug carriers with TSPs significantly increases the quantity of cargo in target tumor cells. [11,12] It also helps to prevent potential side effects after a systemic administration. ...
... docetaxel, doxorubicin (DOX), and paclitaxel 63 ), small molecule cancer drugs (e.g. kinase inhibitors 64 ), antibodies 65 , peptides 66 , and nucleic acids 67 complexed with NPs have been studied for this purpose. Moreover, NPs can be administered using a wider variety of different routes, including oral, nasal, transdermal, and intraocular administration 68 . ...
... 60,61 We suspect that, because DIV3W is not functionalized with an active targeting component, this may contribute to nonspecific delivery. Several studies have incorporated an active targeting moiety to increase tumor targeting for peritoneal carcinomas and metastasis [62][63][64] ; however, there have been conflicting results on whether a targeting component increases tumor targetability for IP delivery. Nonetheless, intratumoral administration of treatments into SQ tumors exhibited significant tumor uptake and warranted further investigation through bioactivity and anticancer studies. ...
... A significant proportion of their ATP is still produced via OXPHOS, again suggesting that at least some mitochondrial function is preserved in tumor cells. Similar to tumor cells, immune cells always shift to glycolysis to support their rapid growth and production of biosynthetic factors for C1QBP as a prognostic marker is related to metastasis and poor prognosis in cancer patients (Chen et al., 2009;Niu et al., 2015;Wang et al., 2015) C1QBP interacts with PKC to modulate in cancer cell chemotaxis (Zhang et al., 2013) C1QBP as a new target can be utilized for precise delivery of imaging or therapeutic agents to tumors (Sanchez-Martin et al., 2011) C1QBP as a tumor biomarker is tightly associated with the lymph node and peritoneal metastasis in epithelial ovarian cancer patients (Yu et al., 2013) C1QBP is involved in tumor invasion and migration (Prakash et al., 2011) C1QBP antibody inhibits growth factor stimulated lamellipodia formation, cell migration and focal adhesion kinase activation as well as prevents even angiogenesis (Kim et al., 2016) C1QBP as a critical regulator for tumor progression of prostate cancer is positively correlated with pathological stage and relapse of the disease (Amamoto et al., 2011) C1QBP promotes tumor metastasis by targeting EMT markers, and modulating TME (Sinha et al., 2021) C1QBP as the receptor of a nanoparticle drug, CGKRK nanoworms, has been found to be effective in orthotopic glioblastoma and breast cancer (Agemy et al., 2013) C1QBP as a tumor diagnostic marker is correlated with progression and poor prognosis of the gastric cancer patients (Gao et al., 2016) C1QBP shifts tumor metabolism to OXPHOS leading to the enhanced tumorigenicity (Fogal et al., 2010) A C1QBP binding peptide displays improved tumor penetration and increased efficacy in suppressing breast tumor growth in vivo (Hunt et al., 2017) C1QBP as a tumor associated antigen (TAA) is overexpressed in clinic low-and high-grade gliomas (Rousso-Noori et al., 2021) C1QBP impacts the lamellipodia formation and a concomitant decrease in FAK kinase, thus promoting tumor migration and tumorigenesis (Kim et al., 2011) C1QBP-specific CAR T cells recognize and specifically eliminate C1QBP expressing glioma cells and tumor derived endothelial cells (Rousso-Noori et al., 2021) Frontiers in Physiology frontiersin.org differentiation into effector cells (Kouidhi et al., 2017). ...
... 60,61 We suspect that, because DIV3W is not functionalized with an active targeting component, this may contribute to nonspecific delivery. Several studies have incorporated an active targeting moiety to increase tumor targeting for peritoneal carcinomas and metastasis [62][63][64] ; however, there have been conflicting results on whether a targeting component increases tumor targetability for IP delivery. Nonetheless, intratumoral administration of treatments into SQ tumors exhibited significant tumor uptake and warranted further investigation through bioactivity and anticancer studies. ...
... There were two studies that included two cell lines: Tamura et al. used both gastric-and liver cancer cell lines [27], and Simón-Gracia et al. used both colon-and gastric cancer cell lines [28]. These are considered here as separate studies. ...
... Covalent attachment of molecules at the compartment surface involves different chemical approaches. For example, strategies based on Cu 2+ -free click chemistry are achieved by: (i) azide-alkyne cycloaddition [106][107][108][109][110], (ii) maleimide and thiol-ene [111][112][113][114][115], and (iii) amine coupling [114,[116][117][118]. Using a combination of strain-promoted azide-alkyne cycloaddition (SPAAC) and thiol-ene reactions, the surface modification of poly(2-methyl-2-oxazoline)-block-poly(dimethylsiloxane) (PMOXA-b-PDMS) polymersomes served to immobilize polymersomes on surfaces [111,112,119]. The functionalization of PMOXA-b-PDMS polymersomes with 4-formylbenzoate facilitated the attachment of hydrazone(HyNic)-functionalized antibodies for biotin [116]. ...